Centre of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
BJOG. 2017 Dec;124(13):1942-1947. doi: 10.1111/1471-0528.14905. Epub 2017 Sep 27.
The synthesis of mifepristone, an antiprogestin blocking the action of progesterone at the receptor level, started a new era of medical termination of pregnancy (MTOP). The initial results of MTOP with mifepristone alone were disappointing; however, mifepristone can sensitise the myometrium to the action of prostaglandins. Clinical trials have shown that the sequential administration of mifepristone followed 1-2 days later by a prostaglandin analogue is a safe, effective, and acceptable method for MTOP. This article will review the events and challenges leading to the development of the current evidence-based and yet off-label regimen for first-trimester MTOP.
This article reviews the events and challenges in the development of medical termination of pregnancy.
米非司酮的合成,一种抗孕激素,在受体水平阻断孕酮的作用,开创了终止妊娠(MTOP)的新纪元。单独使用米非司酮进行 MTOP 的初步结果令人失望;然而,米非司酮可以使子宫肌对前列腺素的作用敏感。临床试验表明,米非司酮序贯给药,1-2 天后再给予前列腺素类似物,是一种安全、有效、可接受的早孕 MTOP 方法。本文将回顾导致目前基于循证但仍为非适应证的早孕 MTOP 方案发展的事件和挑战。
本文回顾了终止妊娠发展过程中的事件和挑战。